title: Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy.
abstract: Activation of human natural killer (NK) cells is associated with the cleavage of CD16 from the cell surface, a process mediated by matrix metalloproteinases (MMPs). In this report, we examined whether inhibition of MMPs would lead to improved NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) function. Using an in-vitro ADCC assay, we tested the anti-tumour function of NK cells with three different therapeutic monoclonal antibodies (mAbs) in the presence of MMPs inhibitor GM6001 or its control. Loss of CD16 was observed when NK cells were co-cultured with tumour targets in the presence of specific anti-tumour antibodies, and was found particularly on the majority of degranulating NK responding cells. Treatment with MMPs inhibitors not only prevented CD16 down-regulation, but improved the quality of the responding cells significantly, as shown by an increase in the percentage of polyfunctional NK cells that are capable of both producing cytokines and degranulation. Furthermore, MMPs inhibition resulted in augmented and sustained CD16-mediated signalling, as shown by increased tyrosine phosphorylation of CD3ζ and other downstream signalling intermediates, which may account for the improved NK cell function. Collectively, our results provide a foundation for combining MMPs inhibitors and therapeutic mAbs in new clinical trials for cancer treatment.
authors.affiliation: Laboratory of Molecular and Developmental Immunology, Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA.
authors.forename: Q
authors.initials: Q
authors.lastname: Zhou
authors.forename: A
authors.initials: A
authors.lastname: Gil-Krzewska
authors.forename: G
authors.initials: G
authors.lastname: Peruzzi
authors.forename: F
authors.initials: F
authors.lastname: Borrego
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects*; D000954:Antigens, Surface / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017252:CD3 Complex / Q000378:metabolism; D015550:Cell Degranulation / Q000187:drug effects; D045744:Cell Line, Tumor; D000068818:Cetuximab; D018920:Coculture Techniques; D016207:Cytokines / Q000097:blood; D004151:Dipeptides / Q000494:pharmacology*; D015536:Down-Regulation / Q000187:drug effects; D058851:GPI-Linked Proteins / Q000378:metabolism; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects; D061965:Matrix Metalloproteinase Inhibitors / Q000494:pharmacology*; D020782:Matrix Metalloproteinases / Q000502:physiology*; D010766:Phosphorylation / Q000187:drug effects; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D017452:Receptors, IgG / Q000378:metabolism; D000069283:Rituximab; D015398:Signal Transduction / Q000187:drug effects; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000954:Antigens, Surface; D000970:Antineoplastic Agents; D017252:CD3 Complex; C121704:CD3 antigen, zeta chain; D016207:Cytokines; D004151:Dipeptides; C428200:FCGR3B protein, human; D058851:GPI-Linked Proteins; D061965:Matrix Metalloproteinase Inhibitors; C078131:N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide; D017452:Receptors, IgG; D000069283:Rituximab; D020782:Matrix Metalloproteinases; D000068878:Trastuzumab; D000068818:Cetuximab